Product Information
ABILIFY MAINTENA ER 400 MG VL is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2860.9798 per EA under NDC 59148024512. Its NADAC has been published 55 times since Jun 11, 2025.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148024512
Classification
Brand
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971On Market Since
2/28/2025
Price Statistics
The NADAC for ABILIFY MAINTENA ER 400 MG VL has been published 55 times since Jun 11, 2025, and over the history we have for it it has risen 3.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2860.9798 per EA |
|---|---|
| All-time high | $2860.9798 (Jun 24, 2026) |
| All-time low | $2771.0251 (Oct 22, 2025) |
| 52-week high | $2860.9798 |
| 52-week low | $2771.0251 |
| Median price | $2777.9002 |
| Average price | $2810.8441 |
| Largest weekly change | +3.0% (Jan 14, 2026) |
| Weeks tracked | 55 |
| Tracking since | Jun 11, 2025 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 25% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 400 MG VL?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 400 MG VL, manufactured by Otsuka America Pharmaceutical Inc., is $2860.9798 per EA (NDC 59148024512), effective Jun 24, 2026.
How has the price of ABILIFY MAINTENA ER 400 MG VL changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 400 MG VL has risen 3.0%. It has been tracked across 55 weekly CMS publications since Jun 11, 2025.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 400 MG VL?
Since Jun 11, 2025, the NADAC for ABILIFY MAINTENA ER 400 MG VL has ranged from a low of $2771.0251 (Oct 22, 2025) to a high of $2860.9798 (Jun 24, 2026), with a median of $2777.9002 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 400 MG VL?
Yes. 1 NADAC-published product shares the same active ingredient, strength, and dosage form. The lowest-priced option, ABILIFY MAINTENA ER 300 MG SYR, is $2137.3167 per EA — about 25% below ABILIFY MAINTENA ER 400 MG VL.
Who manufactures ABILIFY MAINTENA ER 400 MG VL?
ABILIFY MAINTENA ER 400 MG VL (NDC 59148024512) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification